



April 15, 2019

Novartis Pharma AG  
CH-4002, Basel, Switzerland

Reference: EudraCT 2015-004440-19/ Novartis Protocol ID CLAM320B2202

A 30-month multicenter, phase 2b/3, randomized, open label trial to evaluate the efficacy and safety of clofazimine administered orally in addition to background regimen compared to background regimen alone in the treatment of patients with multidrug-resistant pulmonary tuberculosis

Trial CLAM320B2202 was cancelled with no patient enrollment and as such, no results will be reported.